What an Investor Needs from a Startup with Randy Berholtz from Mesa Verde Venture Partners

Early-Stage Life Sciences Investing

Randy discussed his background in investing, explaining that he transitioned from being a lawyer with an MBA to working as a CEO and now invests through Mesa Verde Venture Partners, an early-stage life sciences venture fund in San Diego. He typically invests $500,000 to $1 million in US companies as the first VC investor, with an additional $1 million in reserves. Randy expressed his interest in identifying promising opportunities early and looking 20 years ahead in his investments.

Biotech Startup Investment Guidance

Randy explained that startups should prepare a detailed presentation specifying the problem to be solved and their exit strategy, including potential buyers and competition. He emphasized that biotech startups particularly need to demonstrate market viability, asking whether someone will pay for their product, whether through insurance or direct pay. Randy indicated his investment focus spans therapeutics, diagnostics, medical devices, and healthcare improvements, with personal interest in longevity and health span technologies.

Academia to Biotech Transition Guidance

Randy advised that scientists transitioning from academia to biotech should focus on commercialization rather than just basic science, emphasizing the importance of teamwork and people skills in the industry. He highlighted that successful biotech companies require collaboration across multiple disciplines including chemists, biologists, engineers, marketing, sales, regulatory, and clinical trial personnel. Randy noted that the average time to bring a drug to market is about 12 years, and successful commercialization requires working with diverse teams rather than focusing solely on scientific expertise.

FDA Impact on Medical Technology

Randy discussed the impact of FDA shakeups on the industry, stating that while some change is beneficial, delays in SBIR and STTR programs could hurt science and investing in the long term. He emphasized the need for more government certainty and less politics in the regulatory process, particularly regarding medical technology approvals. The conversation concluded with Mary providing contact information for Randy's venture capital firm and promoting her startup services.

Randy's link: https://mesaverdevp.com

Book a call with Mary Scott at https://calendly.com/businessriff/15min